The DOI matches its Crossref record; 231 of the 232 references it cites were found in a registry or an index.
Cerebral amyloid angiopathy and Alzheimer disease — one peptide, two pathways
Open accessAbstract
The shared role of amyloid-β (Aβ) deposition in cerebral amyloid angiopathy (CAA) and Alzheimer disease (AD) is arguably the clearest instance of crosstalk between neurodegenerative and cerebrovascular processes. The pathogenic pathways of CAA and AD intersect at the levels of Aβ generation, its circulation within the interstitial fluid and perivascular drainage pathways and its brain clearance, but diverge in their mechanisms of brain injury and disease presentation. Here, we review the evidence for and the pathogenic implications of interactions between CAA and AD. Both pathologies seem to be driven by impaired Aβ clearance, creating conditions for a self-reinforcing cycle of increased vascular Aβ, reduced perivascular clearance and further CAA and AD progression. Despite the close relationship between vascular and plaque Aβ deposition, several factors favour one or the other, such as the carboxy-terminal site of the peptide and specific co-deposited proteins. Amyloid-related imaging abnormalities that have been seen in trials of anti-Aβ immunotherapy are another probable intersection between CAA and AD, representing overload of perivascular clearance pathways and the effects of removing Aβ from CAA-positive vessels. The intersections between CAA and AD point to a crucial role for improving vascular function in the treatment of both diseases and indicate the next steps necessary for identifying therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, brains from COVID patients also show ischemic and hemorrhagic lesions, as well as microglial activation [79], which can be seen in many AD patients with cerebral amyloid angiopathy [80].”
From What would it take to prove that a chronic infection is a causal agent in Alzheimer’s disease? (2025) · cites this paper as [80]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recently, vascular deposits of Aβ peptides (amyloid angiopathy) are increasingly recognized as a common pathology in AD cases, supporting that Aβ peptides circulate within the interstitial fluid, including CSF, and blood vessels through perivascular (e.g. lymphatic) drainage pathways during the crosstalk between the brain and the vascular system [77].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, vascular deposits of Aβ peptides (amyloid angiopathy) are increasingly recognized as a common pathology in AD cases, supporting that Aβ peptides circulate within the interstitial fluid, including CSF, and blood vessels through perivascular (e.g. lymphatic) drainage pathways during the crosstalk between the brain and the vascular system [77].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [77]
The cited source says what the claim attributes to it.
In the citing paper
“Inflammation does, however, not seem to be a major component in CAA-related microhemorrhage or microinfarction [38], with the exception of a rare clinical subtype: CAA-related inflammation [6].”
From Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy (2021) · cites this paper as [6]
In the citing paper
“AQP4 levels are reduced in CAA; since AQP4 plays a vital role in glymphatic Aβ clearance in AD brain parenchyma, this consequently impairs Aβ clearance [606, 608].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [608]
In the citing paper
“AQP4 levels are reduced in CAA; since AQP4 plays a vital role in glymphatic Aβ clearance in AD brain parenchyma, this consequently impairs Aβ clearance [606, 608].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [608]
In the citing paper
“Chronic inflammation‐induced disruption of the BBB is an early biomarker of human cognitive dysfunction and often leads to dementia, 113 and both Aβ deposits and tau pathology aggravate vascular damage. 114 , 115”
From Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies (2024) · cites this paper as [115]
In the citing paper
“There is overwhelming evidence for cerebrovascular alterations in AD pathology and amyloid-β deposition around leptomeningeal vessels is a hall mark of cerebral amyloid angiopathy, occurring in almost all AD patients”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Greenberg et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Iliff, J. J., Wang, M., Liao, Y., Plogg, B. A., Peng, W., Gundersen, G. A., Benveniste, H., Vates, G. E., Deane, R., Goldman, S. A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003748 · Cited by 5,824
Sleep Drives Metabolite Clearance from the Adult Brain
Xie, L., Kang, H., Xu, Q., Chen, M. J., Liao, Y., Thiyagarajan, M., O’Donnell, J., Christensen, D. J., Nicholson, C., Iliff, J. J., et al. (2013) · Science · doi:10.1126/science.1241224 · Cited by 5,411
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
The Cellular Phase of Alzheimer’s Disease
De Strooper, B., & Karran, E. (2016) · Cell · doi:10.1016/j.cell.2015.12.056 · Cited by 1,990
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Sorted by citations
Items 501–600 of 954
Omileke, D., Bothwell, S. W., Pepperall, D., Beard, D. J., Coupland, K., Patabendige, A., & Spratt, N. J. (2021) · Brain Sciences · doi:10.3390/brainsci11121589 · Cited by 7
Holtman, I. R., Glass, C. K., & Nott, A. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-55529-9_29 · Cited by 6
Positron Emission Tomography in Cerebral Amyloid Angiopathy: A Scoping Review
Zedde, M., Piazza, F., & Pascarella, R. (2025) · Applied Sciences · doi:10.3390/app15073973 · Cited by 6
Mouse models of Anti-Aβ immunotherapies
Pikus, P., Turner, R. S., & Rebeck, G. W. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00836-x · Cited by 6
Theodorou, A., Melanis, K., Athanasaki, A., Palaiodimou, L., Stefanou, M., Tsalouchidou, P., Vasilopoulos, E., Kouzoupis, A. V., Themistocleous, M. S., Paraskevas, G. P., et al. (2025) · European Stroke Journal · doi:10.1177/23969873251349657 · Cited by 6
Zhu, Q., Song, Y., Qian, Y., Zhang, R., Xue, J., & Hou, Y. (2025) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2025.25 · Cited by 6
Independent effects of white matter lesion volume and APOE ɛ4 on ARIA‐H in A4 Study
Shirzadi, Z., Schultz, A. P., Loghmani, N., Yang, H., Ford, J. N., Yaari, R., Properzi, M. J., Yau, W. W., Liu, L., Rafii, M. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70751 · Cited by 6
Self-citationZhang, B., Yu, X., & Zhang, X. (2026) · Neurological Sciences · doi:10.1007/s10072-026-08893-w · Cited by 6
Toxic mechanisms of amyloid oligomers and therapeutic strategies
Ivanova, M. I., Rosa, C. L., & Ramamoorthy, A. (2026) · Protein Science · doi:10.1002/pro.70519 · Cited by 6
Alameen, A. A. M., Al‐kuraishy, H. M., Al-Gareeb, A. I., Shokr, M. M., & Batiha, G. E. (2026) · Microvascular Research · doi:10.1016/j.mvr.2026.104947 · Cited by 6
Haußmann, R., Homeyer, P., Sauer, C., Grey, A., Krukowski, P., Brandt, M., Donix, M., & Linn, J. (2023) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.6015 · Cited by 6
Vascular Heparan Sulfate and Amyloid-β in Alzheimer’s Disease Patients
McMillan, I. O., Gearing, M., & Wang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073964 · Cited by 7
Gainey, M., Niles, A., Nathaniel, S. I., Goodwin, R. L., Roley, L. T., Win, O., Nathaniel, T. I., & Imeh‐Nathaniel, A. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.04.019 · Cited by 6
Lv, Y. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112786 · Cited by 6
Muir, R. T., Callum, J. L., Yu, A., Kapral, M. K., Swartz, R. H., Black, S. E., MacIntosh, B. J., Fergusson, D. A., Kleinman, S. H., Demchuk, A. M., et al. (2024) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2024.150858 · Cited by 6
Monogenic causes of cerebral small vessel disease and stroke
Guey, S., & Chabriat, H. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-323-99209-1.00018-1 · Cited by 6
Chern, H., Caruso, G., Desaire, H., & Jarošová, R. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00596 · Cited by 6
Altered Clearance and Amyloid-Related Imaging Abnormalities
Cogswell, P. M., Burkett, B. J., Johnson, D. R., & Pillai, J. J. (2025) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2024.12.002 · Cited by 6
Yin, X., Sun, J., Wang, X., Wu, W., Chen, Z., Zhang, D., Xu, Y., Chen, Y., Qiu, W., Qian, X., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70100 · Cited by 6
Song, X., Jin, C. J., Luan, M., & Zheng, X. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1483842 · Cited by 6
Sveikata, L., Zotin, M. C. Z., Schoemaker, D., Ma, Y., Perosa, V., Chokesuwattanaskul, A., Charidimou, A., Duering, M., Gurol, M. E., Assal, F., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.124.039087 · Cited by 6
Self-citationClinical Management in Alzheimer’s Disease in the Era of Disease-Modifying Therapies
Guo, M. H., & Vaishnavi, S. (2023) · Current Treatment Options in Neurology · doi:10.1007/s11940-023-00750-x · Cited by 6
Rodríguez-López, A., Torres-Paniagua, A. M., Acero, G., Díaz, G., & Gevorkian, G. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578150 · Cited by 6
Implication of Small Vessel Disease MRI Markers in Alzheimer’s Disease and Lewy Body Disease1
Park, M.-C., Baik, K., Lee, Y., Kang, S. W., Jung, J. H., Jeong, S. H., Lee, P. H., Sohn, Y. H., & Ye, B. S. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210669 · Cited by 6
Screening for Core Genes Related to Pathogenesis of Alzheimer’s Disease
Yang, L.-X., Qin, Y. H., & Jian, C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.668738 · Cited by 7
ARSD is responsible for carcinoma and amyloidosis of breast epithelial cells
Lin, Y., Fan, L., Zhang, R., Pan, H., & Li, Y. (2022) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2022.151199 · Cited by 6
Integrative Spatial Omics for Systems-Level Mapping of Pathological NichesPreprint
Kruse, A. R. S., Lardenoije, R., Migas, L. G., Scott, C. F., Marshall, C. R., Malek, M. C., Eskaros, A., Pham, T. H., Aamodt, K. I., Colley, M. E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.12.675904 · Cited by 6
Vervuurt, M., Kuiperij, H. B., de Kort, A. M., Kersten, I., Klijn, C. J. M., Schreuder, F. H. B. M., & Verbeek, M. M. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01473-0 · Cited by 5
Charidimou, A., & Baron, J. (2025) · Stroke · doi:10.1161/strokeaha.125.051482 · Cited by 5
Mervosh, N. L., Bilici, N., Wısnıewskı, T., & Devi, G. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251366657 · Cited by 5
Sena, P. P., Friedrich, L., Villarreal, A. E., Fath, F., Sopco, L., Hernández‐Guillamón, M., Pereira, M. L. S., Britton, G. B., Weber, J. J., & Schmidt, T. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1681079 · Cited by 6
Therapeutic and Diagnostic Roles of MSC‐Derived Exosomes in Alzheimer's Disease
Patil, V. S., Parekh, B. K., Sharma, A., Farah, H., Renuka Jyothi, S., Mishra, S. S., Nanda, A., Al-Hasnaawei, S., & Kumar‐Mishra, M. (2025) · Brain and Behavior · doi:10.1002/brb3.71112 · Cited by 6
Yang, J., Zhao, X., Liu, Y., Cai, Y., & Fan, Y. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100449 · Cited by 6
Li, Z., Tan, B., Dong, K., Yu, X., Zhang, S. W., Luo, L., Yao, W., Qin, Z., & Wu, F. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117779 · Cited by 5
Merkel, J., Perneczky, R., Jessen, F., Frölich, L., Jansen, O., Peters, S., Berg, D., Schulz, J. B., & Bartsch, T. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02022-7 · Cited by 5
Dysfunction of the neurovascular unit as a temporal driver in Alzheimer’s pathogenesis
Wang, L., Han, L., & Liu, S. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00548-2 · Cited by 6
Cognition in (pre)symptomatic Dutch‐type hereditary and sporadic cerebral amyloid angiopathy
van Dort, R., Kaushik, K., Rasing, I., van der Zwet, R. G. J., Schipper, M. R., van der Grond, J., van Rooden, S., van Zwet, E. W., Terwindt, G. M., Middelkoop, H. A. M., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14171 · Cited by 5
Beneficial and Detrimental Effects of Uric Acid on Alzheimer’s Disease
Товчига, О. В., & Inkielewicz‐Stępniak, I. (2025) · Current Neuropharmacology · doi:10.2174/011570159x349365250128072146 · Cited by 5
N-Acetylcysteine for Hereditary Cystatin C Amyloid Angiopathy
Snorradóttir, Á. Ó., Gutiérrez-Uzquiza, Á., Bragado, P., March, M., Kao, C., Arkink, E. B., Jónsdóttir, S., Sigurdardottir, A., Ísaksson, H. J., Mariasdóttir, H. L., et al. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0326 · Cited by 5
Schwartz, N. U., Dietz, C. D., Araújo, I. P., Villanueva-Meyer, J. E., Chiong, W., Lane‐Donovan, C., VandeVrede, L. A., Ljubenkov, P. A., Wang, Y., Soleimani‐Meigooni, D. N., et al. (2025) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200508 · Cited by 5
Martín‐Jiménez, P., Sánchez-Tornero, M., Velasco, S. L., Guerrero‐Molina, M. P., González‐Sánchez, M., Martín, A. H.-S., Blanco-Palmero, V. A., Calleja, P., Francisco-Gonzalo, J., Hilario, A., et al. (2021) · Neurología · doi:10.1016/j.nrl.2020.12.008 · Cited by 5
Gan, J., Zhou, H., Liu, C., & Fang, L. (2023) · Neurological Sciences · doi:10.1007/s10072-023-06602-5 · Cited by 5
Hebestreit, S., Schwahn, J., Sandikci, V., Maros, M. E., Valkadinov, I., Yilmaz, R., Eckrich, L., Loghmani, S. B., Lesch, H., Conrad, J., et al. (2023) · Neurogenetics · doi:10.1007/s10048-023-00723-x · Cited by 5
Jeong, H., Pan, Y., Akhter, F., Volkow, N. D., Zhu, D., & Du, C. (2024) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x241304893 · Cited by 5
Zhang, Q., Wang, A., Meng, X., Liao, X., Zhang, Y., Hou, H., Niu, L., Li, R.-P., Guo, W., & Wang, Y. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/9958851 · Cited by 5
Kinetics of amyloid accumulation in physiological viscosity
Kuragano, M., Yamanaka, S., & Tokuraku, K. (2022) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2022.112449 · Cited by 5
Sotoudeh, H., Alizadeh, M., Shahidi, R., Shobeiri, P., love, N., & Singhal, A. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.10.023 · Cited by 5
Cognitive Versus Hemorrhagic Onset in Cerebral Amyloid Angiopathy: Neuroimaging Features
Perini, G., Ramusino, M. C., Farina, L. M., Fabbro, B. D., Canavero, I., Picascia, M., Muzic, S. I., Ballante, E., Cavallini, A. M., Pichiecchio, A., et al. (2023) · Current Alzheimer Research · doi:10.2174/1567205020666230713151211 · Cited by 5
Role of white matter hyperintensity in effects of apolipoprotein E on cognitive injury
Raber, J., & Silbert, L. C. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1176690 · Cited by 5
Gao, F., Shang, S., Chen, C., Dang, L., Gao, L., Wei, S., Wang, J., Huo, K., Deng, M., Wang, J., et al. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.557005 · Cited by 5
Debette, S., Caro, I., Western, D., Namba, S., Sun, N., Kawaguchi, S., He, Y., Fujita, M., Roshchupkin, G., D'Aoust, T., et al. (2024) · doi:10.21203/rs.3.rs-4535534/v1 · Cited by 5
Coexisting Biopsy-Diagnosed Dementia and Glioblastoma
Fetcko, K., Batich, K. A., Reitman, Z. J., Walsh, K. M., Chamberlin, G., Smith, V. L., Jones, K. A., Cummings, T. J., & Peters, K. B. (2024) · Brain Sciences · doi:10.3390/brainsci14020143 · Cited by 4
Potential benefits of marine-derived compounds for slowing the advancement of Alzheimer’s disease
Malan, A., Choudhary, M., Bamrah, P. K., & kumari, D. (2024) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2024.2409869 · Cited by 4
Grabher, B. J. (2024) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.124.268329 · Cited by 4
Costa, A. S., Exalto, L. G., van der Flier, W. M., Teunissen, C. E., Barkhof, F., Kuijf, H. J., Biessels, G. J., & TRACE-VCI Study Group (2024) · Journal of Alzheimer s Disease · doi:10.1177/13872877241296012 · Cited by 4
Zavarella, M., Cecchetti, G., Rugarli, G., Ghirelli, A., Bottale, I., Orlandi, F., Spinelli, E. G., Santangelo, R., Caso, F., Calloni, S. F., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12910-x · Cited by 4
Unnatural foldamers as inhibitors of Aβ aggregation via stabilizing the Aβ helix
Liu, H., Zhao, X., Chen, J., Win, Y. Y., & Cai, J. (2025) · Chemical Communications · doi:10.1039/d4cc05280c · Cited by 4
Mukherjee, S., Coyle, R. A., Dubois, C., Perez, K. A., McLean, C., Masters, C. L., & Roberts, B. R. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02914-2 · Cited by 5
Characterization of neurodegenerative pathologies in adult and pediatric subjects with Down syndrome
Canan, F., Wick, N., Raisanen, J. M., Burns, D. K., Hatanpaa, K. J., Richardson, T. E., White, C. L., & Daoud, E. V. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251362762 · Cited by 4
Katušić, Z. S., d’Uscio, L. V., & He, T. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108921 · Cited by 4
Santos, A. C., Almeida, F., Gauthreaux, K. M., Mock, C., Kukull, W. A., Crary, J. F., & Oliveira, T. G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70637 · Cited by 5
Zhang, W., Liu, H., Zhang, C., Li, Y., Fang, K., Zhou, Y., Weng, L., Fang, L., Luo, Y., Han, X., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.71044 · Cited by 4
Li, J., Li, A., Ye, C., Zhang, L., Jiang, M., Lan, G., González‐Ortiz, F., Yang, J., Zhu, Y., Cai, Y., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00926-4 · Cited by 4
Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy
Benzinger, T. L. S., Cogswell, P. M., Arani, A., Chaney, A. M., Hutson, K., Glasser, M. F., Graff‐Radford, J., McConathy, J., Raji, C. A., Teunissen, C. E., et al. (2026) · The Lancet Neurology · doi:10.1016/s1474-4422(26)00285-1 · Cited by 4
Nagaraja, N., Wang, W., Duara, R., DeKosky, S. T., & Vaillancourt, D. E. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220624 · Cited by 4
Cerebral amyloid deposition predicts long‐term cognitive decline in hemorrhagic small vessel disease
Tsai, Y.-C., Tsai, H.-H. C., Liu, C., Lin, S.-S., Chen, Y., Jeng, J., Tsai, L., & Yen, R. (2023) · Brain and Behavior · doi:10.1002/brb3.3189 · Cited by 4
A translational approach towards understanding brain waste clearance in cerebral amyloid angiopathy
van Veluw, S. J., Benveniste, H., van Osch, M. J. P., Bakker, E. N. T. P., Carare, R. O., Greenberg, S. M., Iliff, J. J., Lorthois, S., Nostrand, W. E. V., Petzold, G. C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae011 · Cited by 4
Self-citationBIOACTIVE COMPOUNDS AND PHARMACOGNOSTIC POTENTIAL OF Tetragonia tetragonioides
Onoiko, O. B. (2024) · Biotechnologia Acta · doi:10.15407/biotech17.01.029 · Cited by 4
tPA supplementation preserves neurovascular and cognitive function in Tg2576 mice
Uekawa, K., Anfray, A., Ahn, S. J., Casey, N., Seo, J., Zhou, P., Iadecola, C., & Park, L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.13878 · Cited by 4
Alaziqi, B. H., Beckitt, L., Townsend, D. J., Morgan, J., Price, R., Maerivoet, A., Madine, J., Rochester, D. L., Akien, G. R., & Middleton, D. A. (2024) · ACS Omega · doi:10.1021/acsomega.4c01281 · Cited by 4
Weidauer, S., Tafreshi, M., Förch, C., Hattingen, E., Arendt, C. T., & Friedauer, L. (2024) · European Journal of Neurology · doi:10.1111/ene.16425 · Cited by 4
Input of exome sequencing in early‐onset cerebral amyloid angiopathy
Grangeon, L., Charbonnier, C., Rousseau, S., Richard, A. C., Quenez, O., Zaréa, A., Boland, A., Olaso, R., Deleuze, J., CAA study group, et al. (2024) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70027 · Cited by 4
Is the Relationship Between Cardiovascular Disease and Alzheimer’s Disease Genetic? A Scoping Review
Moore, A. K., & Ritchie, M. D. (2024) · Genes · doi:10.3390/genes15121509 · Cited by 5
Yu, W., Li, X., Zhang, C., Niu, P., Wu, J., He, W., Gao, K., Li, Y., & Li, Y. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116650 · Cited by 4
Cerebral Amyloid Angiopathy in Alzheimer Disease
Morotti, A., Pilotto, A., Zanola, D., Galli, A., Caratozzolo, S., Gasparotti, R., & Padovani, A. (2024) · Neurology · doi:10.1212/wnl.0000000000210248 · Cited by 4
Allen, J., Ermine, C. M., Lin, R., CLOUD, G. C., Shultz, S. R., & Casillas-Espinosa, P. M. (2025) · Stroke · doi:10.1161/strokeaha.124.049279 · Cited by 4
Prinse, F., van der Weerd, L., Swieten, J. C. V., Ronen, I., Seelaar, H., Hirschler, L., Najac, C., & Dopper, E. G. P. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-102668 · Cited by 4
Tian, M., Li, B., & Shen, L. (2020) · ACS Macro Letters · doi:10.1021/acsmacrolett.0c00622 · Cited by 4
Successful electroconvulsive therapy for depression in a man with cerebral amyloid angiopathy
Schurgers, G., Arts, B. M. G., Postma, A. A., & de Kort, A. M. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-238922 · Cited by 4
Hasegawa, I., Hirayoshi, Y., Minatani, S., Mino, T., Takeda, A., & Itoh, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126422 · Cited by 4
Li, X., Qin, H., & Li, T. (2022) · Ibrain · doi:10.1002/ibra.12065 · Cited by 4
Subcortical hemorrhage caused by cerebral amyloid angiopathy compared with hypertensive hemorrhage
Yamada, S. M., Tomita, Y., Iwamoto, N., Takeda, R., Nakane, M., Aso, T., & Takahashi, M. (2023) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2023.108076 · Cited by 4
Shirian, S., Tahmasebian, N., Moghadam, B. B., Kiani, F. Z., & Amini, M. R. (2024) · The Neuroscience Journal of Shefaye Khatam · doi:10.61186/shefa.12.3.103 · Cited by 4
Iwase, T., Yoshida, M., Iwasaki, Y., Suzuki, S., Yabata, H., Koizumi, R., Moriyoshi, H., & Yazawa, I. (2021) · Neuropathology · doi:10.1111/neup.12760 · Cited by 4
Vervuurt, M., Zhu, X., Schrader, J. M., de Kort, A. M., Marques, T. M., Kersten, I., van Ton, A. M. P., Abdo, W. F., Schreuder, F. H. B. M., Rasing, I., et al. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12804 · Cited by 4
Self-citationThe connection between cerebral amyloid angiopathy and Alzheimer’s disease
Jäger, H. R. (2023) · European Radiology · doi:10.1007/s00330-023-10462-0 · Cited by 4
WITHDRAWN: Border-associated macrophages in the central nervous system
Sun, R., & Jiang, H. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.109921 · Cited by 4
RetractedWhat would it take to prove that a chronic infection is a causal agent in Alzheimer’s disease?
Brutkiewicz, R. R., Cao, W., Morgan, D., Reis, R. S. D., Suryadevara, V., Willette, A. A., Willette, S. A., Wyatt-Johnson, S. K., & Duggan, M. R. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.05.009 · Cited by 3
Alpha-1-acid glycoprotein as a potential serum biomarker for cerebral amyloid angiopathy
Nishigaki, A., Ishikawa, H., Nishiguchi, Y., Tachibana, K., Kato, N., Matsuda, K., Mori, Y., Matsuyama, H., Matsuura, K., Ii, Y., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251333802 · Cited by 3
Hippocampal Interneurons Shape Spatial Coding Alterations in Neurological Disorders
Ikebara, J. M., Jorge, R. S., Marinho, L. S. R., Higa, G. S. V., Adhikari, A., Reis, F. M., Borges, F. S., Ulrich, H., Takada, S. H., Pasquale, R. D., et al. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05020-2 · Cited by 3
Krick, K. E., Weekman, E. M., Johnson, S. N., Sudduth, T. L., Rogers, C. B., Nicolayson, E. J., Kleinhenz, M. T., & Wilcock, D. M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107013 · Cited by 3
Pharmacogenetics or predictive genetics? APOE testing blurs the lines
Zampatti, S., Peconi, C., Farro, J., Piras, F., Pellicano, C., Caltagirone, C., & Giardina, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1627239 · Cited by 3
Three-dimensional organotypic mouse brain slices to study Alzheimer’s disease pathologies: a review
Humpel, C. (2025) · Frontiers in Dementia · doi:10.3389/frdem.2025.1585124 · Cited by 3
Trostchansky, A., & Alarcón, M. A. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.08.060 · Cited by 3
Regional growth rates of white matter hyperintensities are associated with beta-amyloid burden
Strain, J. F., Rahmani, M., Phuah, C., Dierker, D. L., Luo, J. R., Owen, C., Vlassenko, A. G., Jafri, H., Bourgeat, P., Fripp, J., et al. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.12.006 · Cited by 3
Sha, Y., Jia, C., Liang, M., Wu, J., Zhang, T., Zhu, Y., Yuan, J., Li, Q., Huang, Z., Ruixue, C., et al. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251409418 · Cited by 3
Voigt, S., de Jong, J., Voorter, P., Koemans, E. A., Schipper, M. R., van der Plas, M. C., Kaushik, K., van der Zwet, R. G. J., van Dort, R., van den Brink, H., et al. (2026) · International Journal of Stroke · doi:10.1177/17474930261424089 · Cited by 3
Lu, H., Zhang, Y., Chen, C., Xie, H., Li, Y., & Qiu, S. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03723-4 · Cited by 3
Kim, T. H., Kwon, J. G., Chao, J. S. C., Kim, J. W., Pak, C. J., Suh, H.-S., Lim, J.-S., & Hong, J. P. (2026) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2026.100533 · Cited by 3
Jiang, T., Yan, F., Liu, B., Li, Q., Wang, K., Ru, X., Hao, Y., Guan, Y., & Wang, Y. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1791011 · Cited by 3
Metadata
- Authors
- Greenberg, S. M., Bacskai, B. J., Hernandez-Guillamon, M., Pruzin, J., Sperling, R., & van Veluw, S. J.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Greenberg, Steven M.
- Venue
- Nature Reviews Neurology
- Published
- 2019-12-11
- Volume
- 16
- Issue
- 1
- Pages
- 30-42
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- PMC
- PMC7268202
- OpenAlex
- W2995183059
- Cited by
- 947
- References
- 232
- Citations by year
- 2026: 146 · 2025: 198 · 2024: 179 · 2023: 154 · 2022: 113 · 2021: 104 · 2020: 52
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG026484)
- National Institute of Neurological Disorders and Stroke (RF1NS110054, R01NS096730, U24NS100591)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- cerebral amyloid angiopathy, Alzheimer's disease, amyloid-beta, amyloid-beta clearance, amyloid-related imaging abnormalities, anti-amyloid immunotherapy, vascular function
- MeSH terms
- Alzheimer Disease, Brain, Humans, Signal Transduction, Amyloid beta-Peptides, Cerebral Amyloid Angiopathy, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
